Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment
Standard
Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. / Pompe, Raisa S; Davis-Bondarenko, Helen; Zaffuto, Emanuele; Tian, Zhe; Shariat, Shahrokh F; Leyh-Bannurah, Sami-Ramzi; Schiffmann, Jonas; Saad, Fred; Huland, Hartwig; Graefen, Markus; Tilki, Derya; Karakiewicz, Pierre I.
in: PROSTATE, Jahrgang 77, Nr. 6, 05.2017, S. 686-693.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment
AU - Pompe, Raisa S
AU - Davis-Bondarenko, Helen
AU - Zaffuto, Emanuele
AU - Tian, Zhe
AU - Shariat, Shahrokh F
AU - Leyh-Bannurah, Sami-Ramzi
AU - Schiffmann, Jonas
AU - Saad, Fred
AU - Huland, Hartwig
AU - Graefen, Markus
AU - Tilki, Derya
AU - Karakiewicz, Pierre I
N1 - © 2017 Wiley Periodicals, Inc.
PY - 2017/5
Y1 - 2017/5
N2 - BACKGROUND: To test discriminant ability of the 2014 ISUP Gleason grade groups (GGG) for prediction of prostate cancer specific mortality (PCSM) after radical prostatectomy (RP), brachytherapy (BT), external beam radiation (EBRT) or no local treatment (NLT) relative to traditional Gleason grading (TGG).METHODS: In the Surveillance, Epidemiology, and End Results (SEER)-database (2004-2009), 2,42,531 non-metastatic prostate cancer (PCa) patients were identified, who underwent local treatment (RP, BT, EBRT only) or NLT. Follow-up endpoint was PCSM. Biopsy and/or pathological Gleason score (GS) were categorized as TGG ≤6, 7, 8-10 or GGG: I (≤6), II (3 + 4), III (4 + 3), IV (8), and V (9-10). Kaplan-Meier plots, multivariable Cox regression analyses and receiver operating characteristics (ROC) area under the curve analyses (AUC) were used.RESULTS: Median follow-up was 76 months (IQR: 59-94). For the four examined treatment modalities, all five GGG strata and all three TGG strata independently predicted PCSM. GGG yielded 1.5-fold or greater HR differences between GGG II and GGG III, and twofold or greater HR differences between GGG IV and GGG V. Relative to TGG, GGG added 0.4-1.1% to AUC.CONCLUSIONS: This large population-based cohort study confirms the added discriminant properties of the novel GGG strata and confirms a modest gain in predictive accuracy. Prostate 77: 686-693, 2017. © 2017 Wiley Periodicals, Inc.
AB - BACKGROUND: To test discriminant ability of the 2014 ISUP Gleason grade groups (GGG) for prediction of prostate cancer specific mortality (PCSM) after radical prostatectomy (RP), brachytherapy (BT), external beam radiation (EBRT) or no local treatment (NLT) relative to traditional Gleason grading (TGG).METHODS: In the Surveillance, Epidemiology, and End Results (SEER)-database (2004-2009), 2,42,531 non-metastatic prostate cancer (PCa) patients were identified, who underwent local treatment (RP, BT, EBRT only) or NLT. Follow-up endpoint was PCSM. Biopsy and/or pathological Gleason score (GS) were categorized as TGG ≤6, 7, 8-10 or GGG: I (≤6), II (3 + 4), III (4 + 3), IV (8), and V (9-10). Kaplan-Meier plots, multivariable Cox regression analyses and receiver operating characteristics (ROC) area under the curve analyses (AUC) were used.RESULTS: Median follow-up was 76 months (IQR: 59-94). For the four examined treatment modalities, all five GGG strata and all three TGG strata independently predicted PCSM. GGG yielded 1.5-fold or greater HR differences between GGG II and GGG III, and twofold or greater HR differences between GGG IV and GGG V. Relative to TGG, GGG added 0.4-1.1% to AUC.CONCLUSIONS: This large population-based cohort study confirms the added discriminant properties of the novel GGG strata and confirms a modest gain in predictive accuracy. Prostate 77: 686-693, 2017. © 2017 Wiley Periodicals, Inc.
KW - Aged
KW - Brachytherapy
KW - Follow-Up Studies
KW - Humans
KW - Male
KW - Middle Aged
KW - Population Surveillance
KW - Prostatectomy
KW - Prostatic Neoplasms
KW - Proton Therapy
KW - SEER Program
KW - Treatment Outcome
KW - Journal Article
KW - Validation Studies
U2 - 10.1002/pros.23316
DO - 10.1002/pros.23316
M3 - SCORING: Journal article
C2 - 28156003
VL - 77
SP - 686
EP - 693
JO - PROSTATE
JF - PROSTATE
SN - 0270-4137
IS - 6
ER -